Výsledky vyhledávání - "Alan C, Moses"

Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events)

Autor: Lars Endahl, Shawn Hoskin, Inger Mollerup, Anders Hvelplund, Alan C. Moses, Hanne Theilgaard, Ida Carøe Helmark, Lene Klixbüll Amby

Publikováno v: Therapeutic Innovation & Regulatory Science. 53:279-286

In 2013, a randomized, double-blind, active comparator-controlled, event-driven cardiovascular outcomes trial (DEVOTE) was initiated to compare the cardiovascular safety of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd66a8b36846e354b438b48adb10feb4
https://doi.org/10.1177/2168479018776943

Zobrazit plný text záznamu

Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus

Autor: Faiez Zannad, Abhinav Sharma, Robert J. Mentz, Mona Fiuzat, Javed Butler, Christopher M. O'Connor, João Pedro Ferreira, Lauren B. Cooper, David Fitchett, Alan C. Moses

Publikováno v: JACC: Heart Failure. 6:813-822

There is increasing recognition of the relationship between diabetes and heart failure (HF). Comorbid diabetes is associated with worse outcomes in patients with HF, and death from HF forms a large burden of mortality among patients with diabetes and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c016012bad116eafc8764949d3a954bc
https://doi.org/10.1016/j.jchf.2018.05.020

Zobrazit plný text záznamu

Concentrations of Intact Insulin Concurs With FDA and EMA Standards When Measured by HPLC in Different Parts of the Distribution Cold Chain

Autor: Anders Dyhr Toft, Morten Hach, Jesper Bjerrum, Lars Holm Wæhrens, Alan C. Moses

Publikováno v: Journal of Diabetes Science and Technology. 13:55-59

Background: The article by Carter and Heinemann raised serious concerns about the concentrations of insulin in vials being sold in US pharmacies. To study the claims made in the manuscript, we reviewed Novo Nordisk data on insulin concentration. Meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5251912b47c8612f66111049919cdda
https://doi.org/10.1177/1932296818783783

Zobrazit plný text záznamu

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

Autor: Steven P. Marso, John B. Buse, Bernard Zinman, Melissa V. Hansen, Scott S. Emerson, Darren K. McGuire, Charlotte T. Hansen, Thomas Mark, Thomas R. Pieber, Richard E. Pratley, Matthew P. Gilbert, Edward Franek, Alan C. Moses

Publikováno v: Diabetes, Obesity & Metabolism

Aims The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or olde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db0cb3a50b12a5e5421a2486e55a084
https://pubmed.ncbi.nlm.nih.gov/30850995

Zobrazit plný text záznamu

Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis

Autor: Randi Grøn, Petra Örsy, Darren K. McGuire, Alan C. Moses, Scott S. Emerson, Neil R Poulter, Bernard Zinman, Richard E. Pratley, Mattis F. Ranthe, Kirstine Brown-Frandsen, Thomas R. Pieber, Martin Lange, Steven P. Marso

Publikováno v: Diabetes. 67

CV safety profiles for insulin degludec (degludec) and insulin glargine 100 units/mL (glargine U100) were established by the DEVOTE and ORIGIN trials. In the LEADER trial, the GLP-1 analog liraglutide significantly reduced risks of MACE and mortality

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1576f940eb29c7fa95cf4f7ff63246b
https://doi.org/10.2337/db18-1065-p

Zobrazit plný text záznamu

Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l’étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Autor: K. Brown Frandsen, Steven P. Marso, Michel Marre, B. Zinman, S.S. Pocock, W.M. Steinberg, R.M. Bergenstal, M.A. Nauck, L. Steen Ravn, N.R. Poulter, Alan C. Moses, JF Mann, Gilbert H. Daniels, S.E. Nissen, John B. Buse

Publikováno v: Médecine des Maladies Métaboliques. 9:316-328

Resume LEADER ® (pour Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results ) est une etude clinique evaluant l’effet a long terme du liraglutide sur l’incidence des evenements cardiovasculaires, chez 9 340 pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3965fc19dc2ee7f660ca08845d5aa601
https://doi.org/10.1016/s1957-2557(15)30080-8

Zobrazit plný text záznamu

Novo Nordisk's Senior Vice President provides insight into diabetes care

Autor: Alan C Moses

Publikováno v: Diabetes Management. 5:57-61

Alan Moses* speaks to Daphne Boulicault, Commissioning Editor: Dr Alan Moses was educated at Duke University and Washington University School of Medicine and received medical training at Barnes Hospital, the NIH and Tufts-New England Medical Center.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48e27c997ff315e32f354538d69c1ef4
https://doi.org/10.2217/dmt.14.57

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání